Breast cancer metastatic

28 trials 14 recruiting MedDRA PT
28 Registered trials
14 Recruiting
18 Unique sponsors
33 Unique IMPs
20 Commercial trials
Drug classes (ATC)
— ATC code not specified 17
N Neurology/Psychiatry (ATC N) 2
L Oncology (ATC L) 9
C Cardiology (ATC C) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 17 substances
SERD 3 substances
CDK inhibitor 2 substances
Antibody-drug conjugate (ADC) 2 substances
PARP inhibitor 1 substance
Monoclonal antibody 1 substance
Taxane 1 substance
Radiopharmaceutical 1 substance
Topoisomerase II inhibitor 1 substance
Monoclonal antibody (tumor, humanized) 1 substance
Kinase inhibitor 1 substance
Checkpoint inhibitor (PD-L1) 1 substance
Statin 1 substance
Phase III: 7 Phase II: 12 Phase I/II: 3 Phase IV: 3 Phase I: 1 Phase I (First in Human): 2

Filter these 28 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 28 trials

Phase III

7 trials
  • Daiichi Sankyo Inc. Commercial
    TRASTUZUMAB DERUXTECAN
    2023-506330-73-00 4 countries 2024 n=64
    Recruiting
  • Daiichi Sankyo Inc. Commercial
    TRASTUZUMAB DERUXTECAN; TRASTUZUMAB EMTANSINE
    2024-511204-16-00 4 countries 2019 n=63
    Ended
  • F. Hoffmann-La Roche AG Commercial
    INAVOLISIB; TRASTUZUMAB, PERTUZUMAB
    2022-502046-28-00 7 countries 2023 n=67
    Recruiting
  • F. Hoffmann-La Roche AG Commercial
    ALPELISIB; ALPELISIB, ALPELISIB; INAVOLISIB
    2022-502322-41-00 6 countries 2023 n=150
    Ended
  • Jazz Pharmaceuticals Ireland Limited Commercial
    ZANIDATAMAB
    2023-508960-31-00 8 countries 2024 n=264
    Recruiting
  • Pfizer Inc. Commercial
    2-METHOXY-N-{4-METHOXY-6-[(1H-PYRAZOL-1-YL)METHYL]-1,2-BENZOXAZOL-3-YL}BENZENE-1-SULFONAMIDE
    2025-520566-22-00 14 countries 2025 n=153
    Recruiting
  • Pirkanmaan hyvinvointialue Academic
    ATORVASTATIN
    2024-515109-24-00 1 country 2023 n=240
    Recruiting

Phase II

12 trials
  • Bicycletx Limited Commercial
    ZELENECTIDE PEVEDOTIN
    2024-517868-33-00 4 countries 2025 n=30
    Ended
  • Eisai Limited Commercial
    HUMANISED IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 CONJUGATED TO ERIBULIN
    2023-506866-30-00 3 countries 2024 n=45
    Ended
  • GBG Forschungs GmbH Commercial
    ELACESTRANT DIHYDROCHLORIDE; OLAPARIB
    2023-504925-38-00 1 country 2024 n=176
    Recruiting
  • Jazz Pharmaceuticals Ireland Limited Commercial
    FULVESTRANT; PALBOCICLIB; ZANIDATAMAB
    2023-508135-30-00 1 country 2019 n=86
    Ended
  • Novartis Pharma AG Commercial
    177LU-FAP-2286; CALCIUM FOLINATE; FAP-2286; PACLITAXEL ALBUMIN-BOUND
    2023-508995-12-01 4 countries 2025 n=36
    Recruiting
  • Pfizer Inc. Commercial
    [(1R,3S)-3-[3-[[5-(METHOXYMETHYL)-2-METHYLPYRAZOLE-3-CARBONYL]AMINO]-1H-PYRAZOL-5-YL]CYCLOPENTYL]N-PROPAN-2-YLCARBAMATE MONOHYDRATE; PF-07220060 MONOHYDRATE
    2023-509504-15-00 3 countries 2023 n=49
    Ended
  • Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting Academic
    TRASTUZUMAB DERUXTECAN
    2023-505039-11-00 5 countries 2024 n=112
    Recruiting
  • Institut Curie Academic
    ETOPOSIDE; TRASTUZUMAB; TUCATINIB
    2022-500743-20-00 1 country 2023 n=66
    Recruiting
  • Institut Curie Academic
    TRASTUZUMAB; TUCATINIB
    2024-519624-24-00 1 country n=20
    Pending
  • Institut fuer Frauengesundheit GmbH Academic
    IMP not specified
    2024-519350-37-00 1 country n=89
    Ended
  • Karolinska University Hospital Academic
    ATEZOLIZUMAB; PACLITAXEL ALBUMIN-BOUND
    2022-500808-21-00 1 country 2023 n=64
    Ended
  • Univerzita Palackeho V Olomouci Academic
    IMP not specified
    2024-514665-19-00 1 country 2019 n=150
    Ended

Phase I/II

3 trials
  • Ellipses Pharma Limited Commercial
    ELACESTRANT; VOSILASARM
    2023-507738-26-00 1 country 2024 n=25
    Recruiting
  • Genentech Inc. Commercial
    GIREDESTRANT; RGT-419B
    2025-521128-31-00 4 countries 2025 n=73
    Recruiting
  • Novartis Pharma AG Commercial
    LUTETIUM (177LU)-NEOBOMB1; NEOB
    2023-506717-21-00 6 countries 2024 n=40 Orphan
    Ended

Phase IV

3 trials
  • GE Healthcare Limited Commercial
    IMP not specified
    2024-517400-11-00 1 country 2024 n=165
    Ended
  • Novartis Pharma AG Commercial
    RIBOCICLIB
    2024-514891-41-00 5 countries 2022 n=7
    Ended
  • Rita Fior Academic
    IMP not specified
    2023-509598-22-01 1 country 2025 n=276
    Recruiting

Phase I

1 trial
  • Daiichi Sankyo Inc. Commercial
    IMP not specified
    2023-503965-48-00 3 countries 2024 n=36
    Recruiting

Phase I (First in Human)

2 trials
  • Daiichi Sankyo Inc. Commercial
    DS-3939A
    2023-507937-14-00 3 countries 2025 n=207
    Recruiting
  • Pfizer Inc. Commercial
    PF-07220060 MONOHYDRATE
    2024-512120-11-00 2 countries 2022 n=62
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Daiichi Sankyo Inc. Commercial 4 Phase I, Phase III, Phase I (First in Human) 3
Novartis Pharma AG Commercial 3 Phase II, Phase IV, Phase I/II 1
Pfizer Inc. Commercial 3 Phase II, Phase III, Phase I (First in Human) 1
Jazz Pharmaceuticals Ireland Limited Commercial 2 Phase II, Phase III 1
F. Hoffmann-La Roche AG Commercial 2 Phase III 1
Institut Curie Academic 2 Phase II 1
Bicycletx Limited Commercial 1 Phase II 0
Eisai Limited Commercial 1 Phase II 0
GBG Forschungs GmbH Commercial 1 Phase II 1
GE Healthcare Limited Commercial 1 Phase IV 0
Ellipses Pharma Limited Commercial 1 Phase I/II 1
Genentech Inc. Commercial 1 Phase I/II 1
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting Academic 1 Phase II 1
Institut fuer Frauengesundheit GmbH Academic 1 Phase II 0
Karolinska University Hospital Academic 1 Phase II 0
Univerzita Palackeho V Olomouci Academic 1 Phase II 0
Pirkanmaan hyvinvointialue Academic 1 Phase III 1
Rita Fior Academic 1 Phase IV 1
New trials by year
2019
3
2022
2
2023
6
2024
9
2025
6
← All indication landscapes